Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Petros Christopoulos"'
Autor:
Fabienne Lusky, Hannah Schindler, Mariam Elshiaty, Lena Gaissmaier, Lea Daniello, Farastuk Bozorgmehr, Jonas Kuon, Rajiv Shah, Marc A Schneider, Florian Eichhorn, Philip Baum, Franziska Trudzinski, Arlou Angeles, Florian Janke, Martina Kirchner, Daniel Kazdal, Albrecht Stenzinger, Holger Sültmann, Michael Thomas, Petros Christopoulos
Publikováno v:
Journal of Clinical Oncology. 40:e21141-e21141
e21141 Background: First-line pembrolizumab monotherapy is a standard treatment for metastatic non-small-cell lung cancer (NSCLC) with high PD-L1 expression (TPS ≥50%). However, many patients do not respond, and reliable biomarkers are lacking. Met
Autor:
Yuval Shaked, Michal Harel, Coren Lahav, Ben Yellini, Ella Tepper, Ido Wolf, Tatiana Harkovsky, Raya Leibowitz, Maya Gottfried, Mahmud Abu-Amana, Rivka Katzenelson, Abed Agbarya, Mor Moskovitz, Michal Lotem, Adva Levy-Barda, Alona Zer, Ina Koch, David Paul Carbone, Adam P. Dicker, Petros Christopoulos
Publikováno v:
Journal of Clinical Oncology. 40:e21132-e21132
e21132 Background: To date, predicting response to immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) patients is based on assessing PD-L1 levels in tumor biopsies. However, such assays are only moderately predictive. In a
Autor:
Foteinos-Ioannis D. Dimtrakopoulos, Petros Christopoulos, Mariam Elshiaty, Lea Daniello, Ioannis Pyrousis, Anastasia E Kottorou, Thomas Makatsoris, Haralabos Kalofonos, Angelos Koutras
Publikováno v:
Journal of Clinical Oncology. 40:e21096-e21096
e21096 Background: Ιmmune checkpoint inhibitors (ICIs) have tremendously changed the daily clinical practice on the treatment of advanced non-small cell lung cancer (aNSCLC). However, clinical useful biomarkers remain an unmet need. Recently, a new
Autor:
Athina Christopoulou, Petros Christopoulos, Sofia Agelaki, Eleni Isidora Perdikouri, Thomas Papastergiou, Angelos Koutras, Eleftherios Zervas, Haralabos P. Kalofonos, Evangelos Lianos, Georgios Oikonomopoulos, Sofia Baka, Nikolaos Tsoukalas, Thomas Makatsoris, Ilias Athanasiadis, Kostas N. Syrigos, Vasileios Megalooikonomou, Epaminondas Samantas, Giannis Mountzios, Foteinos-Ioannis D. Dimtrakopoulos, Foteini Kalofonou
Publikováno v:
Journal of Clinical Oncology. 39:e21164-e21164
e21164 Background: The treatment of advanced non-small cell lung cancer (aNSCLC) has tremendously changed during the last few years, especially, since immune checkpoint inhibitors (ICIs) were incorporated in the daily clinical practice. However, clin
Autor:
Stefan Fröhling, Charles Swanton, Solange Peters, Petros Christopoulos, Peter Schirmacher, Michael Allgäuer, Kevin Litchfield, Eugen Rempel, Daniel Kazdal, Albrecht Stenzinger, Michael Thomas, J. Budczies, Volker Endris
Publikováno v:
Journal of Clinical Oncology. 37:2632-2632
2632 Background: Tumor mutational burden (TMB) is an emerging biomarker in immuno-oncology (IO). Panel sequencing (PS) is a promising approach for its implementation in clinical practice. Methods: We analyzed TMB as predictor of IO response in a mult